Table 2

Comparison of incidence of HCC and death or LT

ModelTreatment groupNEvent5-year cumulative incidence (95% CI)*HR (95% CI)†P value
All patients
 HCC
 Crude (general model)Tenofovir143950, 137‡5.587 (4.021 to 7.506)0.912 (0.638 to 1.303)0.6133
Entecavir158384, 409‡5.459 (4.399 to 6.674)Ref
 Adjusted (general model)Tenofovir143950, 137‡0.971 (0.676 to 1.396)0.8751
Entecavir158384, 409‡Ref
 Crude (PSM model)Tenofovir137047, 129‡5.292 (3.815 to 7.104)1.030 (0.703 to 1.509)0.8803
Entecavir137064, 355‡4.816 (3.754 to 6.062)Ref
 Adjusted (PSM model)§Tenofovir137047, 129‡1.077 (0.518 to 2.241)0.8418
Entecavir137064, 355‡Ref
 Death or LT
 Crude (general model)Tenofovir1439222.406 (1.333 to 3.479)1.052 (0.614 to 1.804)0.8530
Entecavir1583372.929 (1.984 to 3.873)Ref
 Adjusted (general model)Tenofovir1439221.110 (0.640 to 1.923)0.7105
Entecavir158337Ref
 Crude (PSM model)Tenofovir1370202.317 (1.229 to 3.406)1.09 (0.622 to 1.911)0.7633
Entecavir1370282.512 (1.580 to 3.445)Ref
 Adjusted (PSM model)§Tenofovir1370200.976 (0.363 to 2.623)0.9611
Entecavir137028Ref
Patients with chronic hepatitis
 HCC
 Crude (general model)Tenofovir95611, 85‡1.861 (0.930 to 3.359)1.031 (0.481 to 2.211)0.9372
Entecavir101617, 269‡1.727 (1.047 to 2.697)Ref
 Adjusted (general model)Tenofovir95611, 85‡1.008 (0.474 to 2.144)0.9831
Entecavir101617, 269‡Ref
 Crude (PSM model)Tenofovir87710, 77‡1.725 (0.832 to 3.200)0.923 (0.420 to 2.028)0.8411
Entecavir87716, 233‡1.890 (1.127 to 2.985)Ref
 Adjusted (PSM model)§Tenofovir87710, 77‡0.462 (0.150 to 1.424)0.1790
Entecavir87716, 233‡Ref
 Death or LT
 Crude (general model)Tenofovir956132.205 (0.914 to 3.496)1.877 (0.841 to 4.189)0.1242
Entecavir1016121.491 (0.642 to 2.339)Ref
 Adjusted (general model)Tenofovir956131.275 (0.354 to 4.586)0.7100
Entecavir101612Ref
 Crude (PSM model)Tenofovir877112.063 (0.749 to 3.378)1.987 (0.836 to 4.722)0.1202
Entecavir87791.307 (0.446 to 2.169)Ref
 Adjusted (PSM model)§Tenofovir877110.925 (0.229 to 3.730)0.9122
Entecavir8779Ref
Patients with liver cirrhosis
 HCC
 Crude (general model)Tenofovir48339, 52‡12.658 (8.759 to 17.301)0.916 (0.613 to 1.369)0.6694
Entecavir56767, 140‡12.196 (9.618 to 15.096)Ref
 Adjusted (general model)Tenofovir48339, 52‡0.991 (0.664 to 1.479)0.9657
Entecavir56767, 140‡Ref
 Crude (PSM model)Tenofovir45135, 49‡12.171 (8.205 to 16.965)0.956 (0.614 to 1.488)0.8419
Entecavir45150, 109‡11.471 (8.687 to 14.676)Ref
 Adjusted (PSM model)§Tenofovir45135, 49‡1.077 (0.435 to 2.662)0.8731
Entecavir45150, 109‡Ref
 Death or LT
 Crude (general model)Tenofovir48392.826 (0.876 to 4.776)0.665 (0.307 to 1.442)0.3017
Entecavir567255.508 (3.371 to 7.645)Ref
 Adjusted (general model)Tenofovir48390.709 (0.322 to 1.559)0.3925
Entecavir56725Ref
 Crude (PSM model)Tenofovir45182.773 (0.743 to 4.802)0.864 (0.369 to 2.024)0.7369
Entecavir451154.196 (2.082 to 6.310)Ref
 Adjusted (PSM model)§Tenofovir45181.004 (0.204 to 4.928)0.9962
Entecavir45115Ref
  • Cox regression models with robust SEs and the sandwich covariance matrix estimation, which accounted for the clustering of matched pairs.

  • *By Kaplan-Meier analysis or cumulative incidence function.

  • †Estimated from Cox proportional hazard model or subdistribution hazard model (model by Fine and Gray).

  • ‡Number of competing risk.

  • §Adjusted for date of antiviral.

  • HCC, hepatocellular carcinoma; LT, liver transplantation; PSM, propensity score matching.